An interventional study of A structured shared follow-up plan combined with patient education in Diabetes Mellitus Type 2, sponsored by Aysenur Aktemur. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Aysenur Aktemur · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 341 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 62 open to participants now, 72 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.
Among the 341 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 154th largest by enrollment of the 265 interventional ones that give a count, is one of 34 that started in 2021, is one of 149 with no phase, and was the 321st registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →62 of the 341 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Hatice Zehra FERHATLAR · Sites in Turkey
Ages 18–65
Ankara Medipol University · Sites in Turkey
Ages 18–74
AstraZeneca · Sites in Turkey, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Turkey, United States, Argentina and 13 more countries
Ages 45+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
341 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 85 · Phase 4 28
First in 2002; this study’s year is marked. 34 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is close to the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 265 interventional studies, 118 across the 75 observational. Of the 259 that completed or were terminated, 80 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 341 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Aysenur Aktemur as lead sponsor.
Aysenur Aktemur has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
26 of the studies in Diabetes Mellitus, Type 2 with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847294Ankara Medipol UniversityThe Effectiveness of an Occupation-Based Lifestyle Program in Individuals With Type 2 Diabetes | 2026-11 |
| NCT07659925Baskent UniversityPeriodization-Based Strength Exercise Training in İndividuals With Type 2 Diabetes | 2026-11 |
| NCT06588894Kutahya Health Sciences UniversityInvestigation of Motor Imagery Ability, Body Awareness and Cognitive Functions in Type 2 Diabetes Mellitus | 2026-11-14 |
| NCT07307430Mustafa Kemal UniversityEffect of Narrative Education on Glycemic Control in Adults With Type 2 Diabetes in Primary Care | 2026-11-15 |
| NCT06704672Hoffmann-La RocheClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus | 2026-11-15 |
Add all 26 to your calendar (.ics) → With an account.
Among the 341 studies in Diabetes Mellitus, Type 2 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate whether patient education provided in conjunction with a structured, shared follow-up plan in primary care strengthens the self-management skills of patients with Type 2 Diabetes (T2DM). The study also aims to determine whether the effect of this intervention is associated with patients' baseline levels of health literacy.
The key questions this study aims to address are as follows:
Participants will go through the following processes in the study:
Participants in the Intervention Group:
For three months, they will attend monthly in-person (or video-based, upon request) follow-up sessions with their family physicians. The first session lasts approximately 45 minutes, the second 20 minutes, and the third 15 minutes.
Together with their doctors, they will complete a "Diabetes (DM) ID Card" and receive education on diabetes care and monitoring for complications.
At home, they will monitor their own blood sugar levels, perform foot checks, and record this data in the "DM Diary" developed by the researchers.
At the clinic, they will undergo screenings for complications such as neuropathy, including foot examinations and the monofilament test, performed by their family physicians.
They will review changes in diet and physical activity with their physicians. At the start of the study and at the end of the third month, they will complete self-management and health literacy assessment scales.
Participants in the Control Group:
For three months, they will receive monthly phone calls from their family physicians lasting approximately 10 minutes, which will include general information about diabetes and reminders about complication screenings (eye, foot, and kidney examinations).
Participants will complete the diabetes self-management assessment scale at the start of the study and again at the end of the third month.
For use in the clinicaltrials.gov registration of this clinical trial, a comprehensive "Detailed Description" text-which does not contradict the "Brief Summary" section or repeat the information contained therein and which includes the technical and scientific background-has been prepared below:
Scientific Rationale and Background The prevalence of diabetes is rapidly increasing worldwide; according to data from the International Diabetes Atlas 2025, an estimated 588.7 million people aged 20-79 have diabetes, and this number is expected to reach 822.5 million by 2050. The TURDEP-2 study conducted across Turkey also revealed a similar upward trend, showing that the prevalence of diabetes rose from 7.2% to 13.7% over a 12-year period (1998-2010). The long-term microvascular and macrovascular complications of diabetes constitute a significant disease burden; for example, diabetic nephropathy-the most common cause of end-stage renal disease in developed countries-develops in 20-40% of people with Type 2 Diabetes (T2DM) and increases the risk of cardiovascular mortality. Additionally, diabetic neuropathy-characterized by symmetrical loss of sensation-and peripheral vascular disease are the primary causes of foot ulcers and form the basis of diabetic foot cases, leading to approximately 12,000 amputations annually across Turkey.
Primary care providers are responsible for regularly monitoring patients with diabetes, recommending screenings for complications, and educating patients on how to protect themselves from these complications. However, effective control of the disease requires patients to take responsibility for managing their own condition (self-management). Individuals with low health literacy (HL) have a higher risk of developing diabetes complications (particularly neurovascular complications and retinopathy), and these patients are less likely to have sufficient knowledge about diabetes care and self-care activities. According to data from the Turkey Health Literacy Survey, 24.5% of the population has inadequate health literacy, while 40.1% has problematic health literacy. Although there are many educational programs in the literature aimed at supporting diabetes self-management, the majority of these studies have been conducted in secondary or tertiary care facilities or specialized diabetes centers; however, access to such multidisciplinary expert teams is quite limited in communities with scarce resources. Therefore, there is a need for structured intervention models that can be implemented at the primary care level, aim to improve self-management skills even among patients with low health literacy, and are based on physician-patient collaboration.
Study Design and Sample Size This study was designed as a pre-test/post-test comparative, non-randomized controlled clinical trial. The study was conducted at three different primary care centers in Istanbul. Instead of randomization, center-based grouping was chosen; patients registered at ASM-A formed the intervention group (IG), while those registered at ASM-B and ASM-C formed the control group (CG). This design was chosen to prevent patients at the same center from interacting with one another and sharing information (the contamination effect).
The study's sample size was calculated using the Clinical Sample Size Calculator (ClinCalc) program, targeting a minimum increase of 8 points in self-management scale scores in the intervention group following the intervention, at a 95% confidence level and 80% power. Accordingly, with a 1:1 ratio, at least 40 participants were planned for each group, and the study was completed with a total of 84 patients.
Theoretical Framework of the Intervention (Theoretical Framework of the Intervention) In educating patients with low health literacy, evidence-based strategies such as using simple language, focusing on direct actions, limiting the number of messages, taking cultural differences into account, supporting instructions with visual aids, and continuously monitoring the patient's level of understanding (teach-back method) have been adopted. Developed in line with these principles, the "Diabetes (DM) ID Card" and "DM Diary" have been visually enriched and prepared in extremely simple language to enable patients to manage their own self-care without being overwhelmed by complex medical information.
Instead of conducting a traditional, one-way educational session, an interactive follow-up model was implemented in which the physician and patient engage in a two-way dialogue, and the patient actively shares their habits and the challenges they face. During this process, patients received in-person training from their physicians on how to perform daily blood glucose monitoring and self-examinations of their feet.
Data Collection Tools and Scales (Measurement Instruments)
Data from participants were collected using the following valid and reliable instruments administered by family physicians at the initial visit and at the end of the third month:
Sociodemographic Questionnaire: A form prepared by the researchers that asks patients about their age, gender, education, income level, smoking and alcohol habits, and comorbidities.
Hacettepe University Adult Health Literacy Scale Short Form (HU-SOÖ): A 24-item measure with two dimensions-Health Literacy and Self-Efficacy-and a Cronbach's alpha value of 0.84. The scale does not have a specific cut-off point; higher scores indicate a higher level of health literacy.
Type 2 Diabetes Self-Management Scale (DÖYÖ): A 19-item scale using a 5-point Likert scale with a Cronbach's alpha value of 0.86. The scale consists of three subscales: "Healthy Lifestyle Behaviors," "Blood Sugar Management," and "Use of Health Services."
Statistical Analysis Plan All data obtained in this study were analyzed using IBM SPSS version 23.0. Categorical variables were described using frequencies and percentages; the distribution of continuous variables was assessed using the Kolmogorov-Smirnov test and by examining kurtosis and skewness values. The chi-square and McNemar tests were used for categorical comparisons between groups. In the analysis of continuous variables, the paired t-test and independent samples t-test were used for data showing a normal distribution; for data not normally distributed, the Wilcoxon signed-rank test was preferred. Correlations between variables were calculated using Pearson or Spearman tests.
An intent-to-treat (ITT) analysis was applied to control for the effect of patients who were lost to follow-up on the analysis. In this context, the post-test scores of 5 patients from each group who were unable to attend follow-up visits for various reasons (unreachability or death) were included in the analysis without assuming any change (while retaining their baseline scores).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: A structured shared follow-up plan combined with patient education
This intervention consists of a structured, patient-centered diabetes self-management program integrated into routine primary care, specifically designed to address low health literacy. Delivered face-to-face (or via video call) by family physicians over three monthly sessions of decreasing duration (approximately 45, 20, and 15 minutes, respectively). It utilizes low-literacy communication strategies, including plain language, action-focused messaging, visual aids, and the 'teach-back' method to confirm and reinforce understanding.
Change in Type 2 Diabetes Self-Management Scale (DSMS) Total Score
The DSMS is a validated 19-item scale designed to assess diabetes self-management skills in patients with type 2 diabetes. It uses a 5-point Likert-type scoring system. The total score ranges from 19 to 95, with higher scores indicating a higher level of diabetes self-management skills. This outcome measure evaluates the change in total self-management skills from baseline to the end of the 3-month follow-up period.
Time frame: Baseline and 3 months
Ran from May 2021 to primary completion in Jan 2022, 8 months.
Of 2,068 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 8 months is below that.
Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.